[{"id":"d74c8729-2895-4f4e-b85a-34aae37b7fae","acronym":"","url":"https://clinicaltrials.gov/study/NCT05872295","created_at":"2023-05-24T18:06:17.125Z","updated_at":"2024-07-02T16:35:25.931Z","phase":"Phase 1","brief_title":"IKS014 in Advanced Solid Tumors That Express HER2","source_id_and_acronym":"NCT05872295","lead_sponsor":"Iksuda Therapeutics Ltd.","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive • HR positive • HER-2 amplification • HER-2 expression","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HR positive • HER-2 amplification • HER-2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e caxmotabart entudotin (IKS014)"],"overall_status":"Recruiting","enrollment":" Enrollment 165","initiation":"Initiation: 09/14/2023","start_date":" 09/14/2023","primary_txt":" Primary completion: 09/01/2025","primary_completion_date":" 09/01/2025","study_txt":" Completion: 09/01/2027","study_completion_date":" 09/01/2027","last_update_posted":"2023-12-18"},{"id":"3c6a97e3-3ccc-4331-867d-74247abeab43","acronym":"","url":"https://clinicaltrials.gov/study/NCT05755048","created_at":"2023-03-06T15:01:36.617Z","updated_at":"2024-07-02T16:35:38.244Z","phase":"Phase 3","brief_title":"FS-1502 Versus T-DM1 for HER2-Positive Unresectable Locally Advanced or Metastatic Breast Cancer","source_id_and_acronym":"NCT05755048","lead_sponsor":"Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Kadcyla (ado-trastuzumab emtansine) • caxmotabart entudotin (IKS014)"],"overall_status":"Recruiting","enrollment":" Enrollment 314","initiation":"Initiation: 03/28/2023","start_date":" 03/28/2023","primary_txt":" Primary completion: 07/30/2025","primary_completion_date":" 07/30/2025","study_txt":" Completion: 01/31/2026","study_completion_date":" 01/31/2026","last_update_posted":"2023-09-01"}]